Orthocell Ltd (ASX:OCC)'s Paul Anderson brings Proactive up to speed on a clinical tendon study with its OrthoATI™ treatment candidate. He says the current standard of care presents no genuine, non-surgical solutions for these kinds of tendon injuries, but the latest study indicates that 95% of the OrthoATI™ patients reported a near-normal level of function at the 12-month mark.
Orthocell finds further success in clinical tendon study
